Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?

AUTHORS

Mohamad Amin Pourhoseingholi 1 , Sara Ashtari 1 , Seyed Moayed Alavian ORCID 2 , *

1 Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

2 Middle East Liver Diseases Center (MELD), Tehran, IR Iran

How to Cite: Pourhoseingholi M A, Ashtari S, Alavian S M. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?, Hepat Mon. Online ahead of Print ; 14(11):25540. doi: 10.5812/hepatmon.25540.

ARTICLE INFORMATION

Hepatitis Monthly: 14 (11); 25540
Published Online: November 22, 2014
Article Type: Editorial
Received: November 21, 2014
Accepted: November 22, 2014
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

This article does not have abstract.

Full Text

Full text is available in PDF

© 2014, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: